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Parkinson’s disease is a principal underlying disease of neuroleptic malignant syndrome 
(NMS) occurring in parkinsonian disorders, but NMS may occur in patients with progres-
sive supranuclear palsy and multiple system atrophy. We report first patient with corticobasal 
degeneration (CBD) who developed NMS after abrupt reduction of antiparkinsonian medi-
cation and concurrent infection. It should be kept in mind that the prevention of infectious 
illness, which is common complication in parkinson-plus syndrome, is important, and dose 
reduction or withdrawal of anti-parkinsonian medications should be carefully performed 
even in the patients with CBD who are expected to be unresponsive to levodopa treatment. 
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Neuroleptic malignant syndrome (NMS) is characterized by high fever, worsening of par-
kinsonian symptoms, elevated serum creatine kinase (CK), altered consciousness, and auto-
nomic instability.1 It is precipitated mainly by withdrawal or reduction of anti-parkinsonian 
medications, but infection, dehydration, poor oral intake, or even hot weather may precipitate 
the illness.2 Additionally, the underlying disease is not confined to Parkinson’s disease (PD), 
but NMS also can be found in atypical parkinsonism.2
However, there is no report of NMS occurred in patient with corticobasal degeneration 
(CBD). We first report a clinically diagnosed CBD patient who developed NMS after reduc-
tion of anti-parkinsonian medications and pneumonia.
Case
A 70 year old woman first visited our clinic for right hand bradykinesia and gait disturbance 
unresponsive to levodopa treatment. At age 67, she started to feel clumsiness in her right hand 
and to walk with very short stride and festination. Her gait disturbance rapidly worsened un-
til she was unable to walk without assistance after two years. At age 69, she was diagnosed 
with PD and started to take levodopa.
At age 70, she took 450 mg of levodopa by regular levodopa/carbidopa, 150 mg by con-
trolled release form of levodopa/carbidopa, 6 mg of ropinirole, and 200 mg of amantadine per 
day, but felt no clinical improvement. She was unable to use her right hand for daily activities. 
Her verbal output was markedly reduced, and she could speak only simple words. On neuro-
logical examination, she showed masked face and no rest tremor. When she stretched out her 
arms, her right elbow showed mild flexion dystonia. Muscle tone was moderately elevated 
in her right limbs and mildly in the left limbs. She could not perform hand rolling, finger tap-
ping, and foot tapping movements with her right limbs. She could not stand still without sup-
port and fell spontaneously. Deep tendon reflexes were normoactive. The stimulus sensitive 
jerks and ideomotor apraxia were observed in her right hand. The unified PD rating scale mo-
tor score was 52. We were unable to check mini-mental status examination score.
A T2-weighted brain magnetic resonance imaging (MRI) study showed diffuse cortical 
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atrophy which was prominent in the left fronto-tempo-pari-
etal cortex, and moderate degree of hypersignal intensities in 
diffuse subcortical white matter. An [18F]-deoxyglucose posi-
tron emission tomography study showed severe hypometab-
olism in left fronto-temporo-parietal cortex, striatum and 
thalamus (Figure 1).
Clinical diagnosis of CBD was made. Because there was no 
response to levodopa treatment, we started to taper off anti-
parkinsonian medications. Three days after abrupt discontinu-
ation of ropinirole, amantadine, and controlled release form of 
levodopa except regular levodopa/carbidopa, she developed 
severe dysphagia and dyspnea. Her mental status was getting 
drowsy and parkinsonian motor deficits rapidly exacerbated. 
She was bed-ridden and unable to move her body in bed. Se-
vere rigidity was observed in her limbs and neck. Her body 
temperature rose up to 39°C and heart rate over 190/min. 
Blood leukocyte count was 16,990/mm3. Serum CK level was 
10,632 IU/L and urine myoglobin level was 2,881 ng/mL. Che-
st X-ray showed bronchopneumonia. There was no interval ch-
ange in brain MRI study.
The dosage of levodopa was increased to 750 mg per day 
and antibiotics treatment was started. During the course of fol-
lowing seven days, body temperature and serum CK level 
slowly returned to the normal level. Severe rigidity of the 
limbs also returned to a moderate degree. However, she re-
mained bed-ridden status even after a year.
Discussion
The PD patients with longer disease duration, higher motor 
severity and motor fluctuation are likely to develop NMS after 
abrupt reduction of anti-parkinsonian medications.3 Abrupt 
deterioration of dopaminergic transmission is suggested to be 
a common pathophysiological mechanism of NMS.2,4 Howev-
er, the NMS can occur in atypical parkinsonisms, including 
progressive supranuclear palsy, multiple system atrophy, and 
CBD, which accompany the pathology in postsynaptic striatal 
neurons and poor levodopa responsiveness.2,5 These suggest 
that peripheral mechanism or the alteration of neurotransmit-
ters other than dopamine may also be involved in the patho-
genesis of NMS.2,4
In this patient, both reduction of levodopa dosage and con-
current infection might precipitate NMS. Therefore, preven-
tion of infection, a common complication of parkinson-plus 
syndromes, is necessary to prevent NMS. Additionally, dose 
reduction or withdrawal of anti-parkinsonian medications 
should be carefully performed even in the patients with CBD 
who are expected to be unresponsive to levodopa treatment.
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Figure 1. [18F]-deoxyglucose brain positron emission tomography 
study of the patient shows markedly reduced glucose metabolism 
in the left fronto-temporo-parietal cortex, left striatum and left thal-
amus.
